Literature DB >> 11353811

Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system.

R Halmosi1, Z Berente, E Osz, K Toth, P Literati-Nagy, B Sumegi.   

Abstract

Ischemia-reperfusion induces reactive oxygen species (ROS) formation, and ROS lead to cardiac dysfunction, in part, via the activation of the nuclear poly(ADP-ribose) polymerase (PARP, called also PARS and ADP-RT). ROS and peroxynitrite induce single-strand DNA break formation and PARP activation, resulting in NAD(+) and ATP depletion, which can lead to cell death. Although protection of cardiac muscle by PARP inhibitors can be explained by their attenuating effect on NAD(+) and ATP depletion, there are data indicating that PARP inhibitors also protect mitochondria from oxidant-induced injury. Studying cardiac energy metabolism in Langendorff heart perfusion system by (31)P NMR, we found that PARP inhibitors (3-aminobenzamide, nicotinamide, BGP-15, and 4-hydroxyquinazoline) improved the recovery of high-energy phosphates (ATP, creatine phosphate) and accelerated the reutilization of inorganic phosphate formed during the ischemic period, showing that PARP inhibitors facilitate the faster and more complete recovery of the energy production. Furthermore, PARP inhibitors significantly decrease the ischemia-reperfusion-induced increase of lipid peroxidation, protein oxidation, single-strand DNA breaks, and the inactivation of respiratory complexes, which indicate a decreased mitochondrial ROS production in the reperfusion period. Surprisingly, PARP inhibitors, but not the chemically similar 3-aminobenzoic acid, prevented the H(2)O(2)-induced inactivation of cytochrome oxidase in isolated heart mitochondria, suggesting the presence of an additional mitochondrial target for PARP inhibitors. Therefore, PARP inhibitors, in addition to their important primary effect of decreasing the activity of nuclear PARP and decreasing NAD(+) and ATP consumption, reduce ischemia-reperfusion-induced endogenous ROS production and protect the respiratory complexes from ROS induced inactivation, providing an additional mechanism by which they can protect heart from oxidative damages.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11353811     DOI: 10.1124/mol.59.6.1497

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  36 in total

Review 1.  Nicotinamide: a jack of all trades (but master of none?).

Authors:  Csaba Szabó
Journal:  Intensive Care Med       Date:  2003-04-24       Impact factor: 17.440

2.  The hypoxic preconditioning agent deferoxamine induces poly(ADP-ribose) polymerase-1-dependent inhibition of the mitochondrial respiratory chain.

Authors:  Ana Cañuelo; Rubén Martínez-Romero; Esther Martínez-Lara; José A Sánchez-Alcázar; Eva Siles
Journal:  Mol Cell Biochem       Date:  2011-12-07       Impact factor: 3.396

3.  Vincristine attenuates N-methyl-N'-nitro-N-nitrosoguanidine-induced poly-(ADP) ribose polymerase activity in cardiomyocytes.

Authors:  Jianqing Zhang; Kanu Chatterjee; Conrad C Alano; Mikaila A Kalinowski; Norman Honbo; Joel S Karliner
Journal:  J Cardiovasc Pharmacol       Date:  2010-03       Impact factor: 3.105

4.  Participation of vanilloid/capsaicin receptors, calcitonin-gene-related peptide and substance P in gastric protection of omeprazole and omeprazole-like compounds.

Authors:  Gyula Mózsik; Zsanett Peidl; János Szolcsányi; András Dömötör; Kálmán Hideg; György Szekeres; Oszkár Karádi; Béla Hunyady
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

5.  Activation of poly(ADP-ribose) polymerase by myocardial ischemia and coronary reperfusion in human circulating leukocytes.

Authors:  Emese Tóth-Zsámboki; Eszter Horváth; Katarina Vargova; Eszter Pankotai; Kanneganti Murthy; Zsuzsanna Zsengellér; Tamás Bárány; Tamás Pék; Katalin Fekete; Róbert Gábor Kiss; István Préda; Zsombor Lacza; Domokos Gerö; Csaba Szabó
Journal:  Mol Med       Date:  2006 Sep-Oct       Impact factor: 6.354

6.  Does the Poly (ADP-Ribose) Polymerase Inhibitor Veliparib Merit Further Study for Cancer-Associated Weight Loss? Observations and Conclusions from Sixty Prospectively Treated Patients.

Authors:  Jason D Doles; Kelly A Hogan; Jennifer O'Connor; Andrea E Wahner Hendrickson; Olivia Huston; Aminah Jatoi
Journal:  J Palliat Med       Date:  2018-05-24       Impact factor: 2.947

7.  A novel insulin sensitizer drug candidate-BGP-15-can prevent metabolic side effects of atypical antipsychotics.

Authors:  Zsuzsanna Literati-Nagy; Kálmán Tory; Botond Literáti-Nagy; Attila Kolonics; László Vígh; László Vígh; József Mandl; Zoltán Szilvássy
Journal:  Pathol Oncol Res       Date:  2012-06-30       Impact factor: 3.201

8.  BGP-15 prevents the death of neurons in a mouse model of familial dysautonomia.

Authors:  Sarah B Ohlen; Magdalena L Russell; Michael J Brownstein; Frances Lefcort
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

Review 9.  Novel neuroprotective strategies in ischemic retinal lesions.

Authors:  Krisztina Szabadfi; Laszlo Mester; Dora Reglodi; Peter Kiss; Norbert Babai; Boglarka Racz; Krisztina Kovacs; Aliz Szabo; Andrea Tamas; Robert Gabriel; Tamas Atlasz
Journal:  Int J Mol Sci       Date:  2010-02-03       Impact factor: 6.208

10.  Influence of PARP-1 polymorphisms in patients after traumatic brain injury.

Authors:  Ajit A Sarnaik; Yvette P Conley; David O Okonkwo; Taura L Barr; Ericka L Fink; Csaba Szabo; Patrick M Kochanek; Robert S B Clark
Journal:  J Neurotrauma       Date:  2010-03       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.